VB-1016 is under clinical development by Nykode Therapeutics and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VB-1016’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VB-1016 overview
VB-1016 is under development for the prevention and treatment of human papillomavirus type 16 (HPV16) induced cancers such as high grade 2/3 cervical intraepithelial neoplasia and HPV16-positive cervical cancer, recurrent head and neck cancer, oropharyngeal cancer, oral cavity cancer, hypopharyngeal cancer, laryngeal cancer anal cancer, penile cancer, vaginal cancer and vulvar cancer. It is a DNA vaccine which is administered by intramuscular route. It is directed at the antigen presenting cells. The vaccine candidate is co-administered with electroporation device. VB-1016 is based on dendritic-cell targeting vaccine platform and Vaccibody technology platform.
Nykode Therapeutics overview
Nykode Therapeutics is a biotech company that carries out the discovery and development of novel immunotherapies, prophylactic and therapeutic vaccines. The company develops VB10.16, a DNA-based immunotherapy targeting malignancies caused by the human papillomavirus. Nykode Therapeutics conducts exploratory safety and immunogenicity studies for HPV16+ immunotherapy VB10.16 in women with high-grade intraepithelial neoplasia. It also researches VB10.COV2 for Covid-19, VB10.NEO for the treatment of cancer and the Regeneron program. The company provides vaccines against human papillomavirus-induced cancer, SARS-CoV-2, melanoma and metastatic tumors. It partners with academic and pharmaceutical companies. Nykode Therapeutics is headquartered in Oslo, Norway.
For a complete picture of VB-1016’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
